BREAST CANCER

A look back at all the FDA news that happened in the month of April 2019, including several new approvals, a priority review, breakthrough designation, and more.

John H. Ward, MD, discusses the role of 21-gene assays in selecting patients with breast cancer for adjuvant chemotherapy treatment.

A new VENTANA HER2 dual in situ hybridization companion diagnostic assay has been launched by Roche to help identify&nbsp;<em>HER2</em> amplification for patients with breast cancer and gastric cancer who could be eligible to receive trastuzumab.

A Case of HR+ Metastatic Breast Cancer

While predictive genetic testing is useful and even crucial for many populations, new medical advances are routinely overhyped in the media and misunderstood by consumers and providers alike.

HR+ Metastatic Breast Cancer

This article focuses specifically on the role of ovarian suppression in young premenopausal women. It reviews methods of ovarian suppression, provides evidence from recent pivotal clinical trials, outlines guidelines for its use, and discusses best practices and practical management applications.

Breast Cancer

Before a community oncology practice considers getting involved in clinical trials research, there are many factorsto consider. Perhaps foremost is the fact that cancer clinical trials provide the evidence base for new advances in oncology.&nbsp;